Tuesday, October 6, 2015

Archive: June, 2012

POSTED: Tuesday, June 5, 2012, 5:41 AM

Compliance enforcement agencies apparently need not look at Teva Pharmaceuticals anymore.

"It is an absolute priority for Teva that our business and people always do the right thing," new chief executive officer Jeremy Levin declared in recent conference call with analysts.

Levin was named Jan. 1 to replace Shlomo Yanai as president and CEO. After finishing his chores at Bristol-Myers Squibb and then spending a couple months learning about Teva, Levin officially took over May 10.

POSTED: Friday, June 1, 2012, 8:06 AM

The Centers for Medicare and Medicaid Services this week announced a partnership to improve - and reduce - the improper use of antipsychotic drugs to treat dementia patients in nursing homes.

Antipsychotic drugs generally have been approved by the U.S. Food and Drug Administration for schizophrenia and bi-polar disorder. They are not approved for dementia. Indeed, several drugs got so-called black box warnings about the dangers of giving such drugs to elderly patients.

Medicare is the federal government's taxpayer-funded medical insurance program for elderly and disabled citizens.

About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell Inquirer Staff Writer
Also on Philly.com:
letter icon Newsletter